Clinical trial of BNC 210 in patients with anxiety disorders in the USA
Latest Information Update: 07 Jan 2013
At a glance
- Drugs BNC 210 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions; Pharmacokinetics
- 21 Dec 2012 Status changed from planning to recruiting based on information reported in a Bionomics media release.
- 28 Nov 2012 New trial record